Thorsten Füreder

Thorsten Füreder

UNVERIFIED PROFILE

Are you Thorsten Füreder?   Register this Author

Register author
Thorsten Füreder

Thorsten Füreder

Publications by authors named "Thorsten Füreder"

Are you Thorsten Füreder?   Register this Author

24Publications

284Reads

43Profile Views

Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer.

Med Oncol 2018 Feb 7;35(3):32. Epub 2018 Feb 7.

Division of Clinical Oncology, Department of Internal Medicine I & Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12032-018-1087-6
Publisher Site
http://dx.doi.org/10.1007/s12032-018-1087-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801394PMC
February 2018

Metal drugs become targeted.

ESMO Open 2017 17;2(3):e000239. Epub 2017 Aug 17.

Department of Medicine I, Institute of Cancer Research, Medical University Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2017-000239DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604710PMC
August 2017

Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

Sci Rep 2016 09 6;6:32946. Epub 2016 Sep 6.

Dept. of Internal Medicine I &CCC, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep32946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011715PMC
September 2016

Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients.

Sci Rep 2016 08 11;6:31498. Epub 2016 Aug 11.

Department of Internal Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep31498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980611PMC
August 2016

Immunotherapy for head and neck squamous cell carcinoma.

Memo 2016;9:66-69. Epub 2016 Jun 20.

Dept. of Internal Medicine I & CCC, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12254-016-0270-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923082PMC
June 2016

Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression.

Eur J Clin Invest 2014 Oct;44(10):958-64

Department of Internal Medicine I & CCC, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/eci.12329DOI Listing
October 2014

Sphingosine kinase 1 is a relevant molecular target in gastric cancer.

Anticancer Drugs 2011 Mar;22(3):245-52

Department of Clinical Pharmacology, Medical University, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/cad.0b013e328340bd95DOI Listing
March 2011

Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.

J Invest Dermatol 2011 Feb 4;131(2):495-503. Epub 2010 Nov 4.

Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2010.327DOI Listing
February 2011

Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.

Cancer Biol Ther 2010 Jun 18;9(11):919-27. Epub 2010 Jun 18.

Department of Clinical Pharmacology, Medical University, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.9.11.11805DOI Listing
June 2010

mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.

Anticancer Res 2008 Nov-Dec;28(6A):3801-8

Section of Experimental Oncology/Molecular Pharmacology, Department of Clinical Pharmacology, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
March 2009

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.

Cancer Biol Ther 2008 Sep 2;7(9):1377-85. Epub 2008 Sep 2.

Section of Experimental Oncology/Molecular Pharmacology, Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.7.9.6416DOI Listing
September 2008